Blueprint Medicines announces approval of AYVAKYT for treatment of ISM patients in Europe

  • Post author:
  • Post category:uncategorized

Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic…

Continue ReadingBlueprint Medicines announces approval of AYVAKYT for treatment of ISM patients in Europe